Publications by authors named "Pierre Clavere"

Claim this Profile
A
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30).
Paul Sargos, Géraldine Pignot, Carine Bellera, Pascal Pommier, Etienne Martin, Pierre Clavere

Radiother Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy of skin cancers.
Emmanuelle Le Fur, Matthieu Pallandre, Adeline Pêtre, Pierre Clavère, Laurent Quéro

Cancer Radiother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Pattern-of-Care Analysis of Primary Cutaneous Lymphomas Radiation Therapy Among European Organisation for Research and Treatment of Cancer Members.
Khaled Elsayad, Emmanuella Guenova, Beatrice Fournier, Carolina Fernandes, Enrico Clementel

Int J Radiat Oncol Biol Phys· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical practice in stereotactic radiotherapy delivery at treatment unit: a practitioner survey and consensus-based recommendations for multidisciplinary professional development.
Nicolas Martz, Vincent Marchesi, Maximilien Rogé, Camille Verry, Pierre Clavère

Radiat Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment.
Eric François, Nicolas Magné, Rabia Boulahssass, Philippe Ronchin, Virginie Huguenet, Pierre Clavere

Radiother Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.
Eric François, Berardino De Bari, Philippe Ronchin, Elodie Nouhaud, Isabelle Martel-Lafay, Pierre Clavere

Eur J Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KLRC3, a Natural Killer receptor gene, is a key factor involved in glioblastoma tumourigenesis and aggressiveness.
Mathilde Cheray, Barbara Bessette, Aurélie Lacroix, Carole Mélin, Soha Jawhari

J Cell Mol Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Jean-François Bosset, Gilles Calais, Laurent Mineur, Philippe Maingon, Suzana Stojanovic-Rundic

Lancet Oncol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiodermatitis prevention with sucralfate in breast cancer: fundamental and clinical studies.
Sabrina Falkowski, Patrick Trouillas, Jean-Luc Duroux, Jean-Marie Bonnetblanc, Pierre Clavère

Support Care Cancer· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98.
Christian Carrie, Jacques Grill, Dominique Figarella-Branger, Valerie Bernier, Laetitia Padovani, Pierre Clavere

J Clin Oncol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression of HIF-1alpha and XRCC4 measured in human samples by real-time RT-PCR using the sigmoidal curve-fitting method.
Hao Qiu, Karine Durand, Hélène Rabinovitch-Chable, Michel Rigaud, Virgile Gazaille

Biotechniques· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Corinne Veyret, Christelle Levy, Philippe Chollet, Yacine Merrouche, Henri Roche, Pierre Clavere

Cancer· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol.
Christian Carrie, Xavier Muracciole, Frédéric Gomez, Jean-Louis Habrand, Mohamed Benhassel, Pierre Clavere

Int J Radiat Oncol Biol Phys· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Jacques Bonneterre, Henri Roché, Pierre Kerbrat, Pierre Fumoleau, Marie-Josèphe Goudier

J Clin Oncol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Pierre Fumoleau, Pierre Kerbrat, Pascale Romestaing, Pierre Fargeot, Alain Brémond

J Clin Oncol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis